Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 5/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352189 | 1.00 | DEGS1 (0.33) | DEGS1XDHABL1ESR2CCR2 | |
| SCHEMBL6352186 | 1.00 | DEGS1 (0.33) | DEGS1XDHABL1ESR2CCR2 | |
| SCHEMBL8337471 | 0.80 | CCR2 (0.39) | DEGS1XDHCCR2KCNH2 | |
| SCHEMBL6277422 | 0.80 | OPRL1 (0.34) | DEGS1ABL1ESR2KDM1AOPRL1 | |
| SCHEMBL6277418 | 0.80 | OPRL1 (0.34) | DEGS1ABL1ESR2KDM1AOPRL1 | |
| SCHEMBL6277424 | 0.80 | OPRL1 (0.34) | DEGS1ABL1ESR2KDM1AOPRL1 | |
| SCHEMBL6699445 | 0.77 | P4HTM (0.43) | KDM1A | |
| SCHEMBL6699442 | 0.77 | P4HTM (0.43) | KDM1A | |
| SCHEMBL13751515 | 0.77 | OPRM1 (0.47) | CCR2KDM1AOPRL1 | |
| SCHEMBL3135453 | 0.75 | ESR1 (0.39) | DEGS1ABL1ESR2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575586-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | Pfizer Japan Inc. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | KAWAI MAKOTO (JP) | 2004-08-05 | — | — | US | disclosed |
| WO-2004054579-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | GRIN1, GRIN3A, GRIN2A | DEGS1 1587/4885XDH 3136/4885ABL1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.